echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Advanced Materials: Wang Hai's team from the National Nano Center has made a new breakthrough in tumor nanovaccines

    Advanced Materials: Wang Hai's team from the National Nano Center has made a new breakthrough in tumor nanovaccines

    • Last Update: 2023-01-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Tumor vaccine refers to the use of tumor antigens to induce the body to produce specific anti-tumor effects through active immunity, stimulate the body's own immune protection mechanism, and achieve the role of
    treating tumors or preventing tumorigenesis.
    Although vaccine-based anti-tumor therapy has a superior theoretical basis, it has not achieved satisfactory clinical treatment results
    .
    Among them, improving the immune stimulation efficiency of vaccines is one of the important research directions in the field of
    tumor immunotherapy.

    On October 11, 2022, the research team of Wang Hai of the National Center for Nanoscience of the Chinese Academy of Sciences published a report in the journal Advanced Materials entitled: Direct Presentation of Tumor-Associated Antigens to Induce Adaptive Immunity by Personalized Dendritic Cell-Mimicking Research paper
    on Nanovaccines.

    In this study, a nanodendritic cell vaccine
    with high efficiency and direct delivery of major histocompatibility complex (MHC)-tumor antigens to T cells was constructed.

    In this study, bone marrow-derived dendritic cells (BMDCs) extracted and induced from mice and tumor cell-bacterial fusion materials were co-incubated by controlling stimulation conditions in vitro, so as to obtain personalized dendritic cell vaccines
    containing MHC-tumor antigen complexes.
    In this study, cell membranes containing personalized MHC-tumor antigen complexes and co-stimulatory factors (CD80/86) will be extracted and coated on folate-iron self-assembled dendritic nanoparticles to construct nanodendritic cell vaccines
    that can directly stimulate T cells to induce specific tumor immune responses.

    The experimental results show that the nanodendritic cells exhibit significant lymph node homing ability and induce specific cellular immunity, effectively inhibit tumor growth and metastasis formation in vivo, and induce long-term immune protection of memory T cells, which is expected to be used in personalized tumor immunotherapy
    .

    a.
    Schematic diagram of synthetic nano-DC vaccine; b-d, SEM and TEM characterization of dendritic nanoparticles; E-f, nanoparticle size distribution and charge characterization; G-i, protein charge, and pull-down assays verify that nano-DC vaccines carry related vaccine-presenting
    protein complexes.

    mRNA technology can synthesize specific tumor antigens through the protein synthesis system of human cells to induce immune response and specifically attack tumor cells, so mRNA tumor vaccines have become another important strategy
    for personalized immunotherapy.

    Lipid nanoparticles (LNPs) serve as non-viral delivery vectors to deliver mRNA to the cytoplasm, and the current ultra-low temperature storage and transport of mRNA-LNPs vaccines hinders their clinical application
    .

    On November 11, 2022, Hai Wang's research team published a research paper entitled: Stabilizing RNA Nanovaccines with Transformable Hyaluronan Dynamic Hydrogel for Durable Cancer Immunotherapy in the journal Advanced Functional Materials

    In this study, a hydrogel-LNPs system (HA-mRLNPs) was developed that can efficiently deliver mRNA encoding tumor antigens to dendritic cells for antigen presentation, inducing antigen-specific CD8+ T cells to kill tumor cells
    .
    It can also be stored
    at room temperature.
    This study proves that stable and durable immunohydrogel-LNPs systems can be used for effective tumor immunotherapy
    .

    To improve the thermostability and durability of mRNA-LNPs vaccines for immune system stimulation, the research team used a deformable hydrogel-LNPs system (HA-mRLNPs) that stores mRNA vaccines at room temperature for in vivo durable immunotherapy
    .
    This study achieved encapsulation of novel LNPs encoding tumor antigen mRNA and immune adjuvants by constructing a highly mixed-efficiency microfluidic chip, followed by dynamic hyaluronic acid hydrogels that restricted the migration and fusion of LNPs to improve the storage time
    of mRNA vaccines at room temperature.

    In addition, hyaluronic acid chains are mobile under physiological conditions and cannot remain gelatinous permanently, so that mRNA nanovaccines can be released in a controlled manner and delivered to dendritic cells, which in turn induce antigen-specific T cells to kill tumor cells
    .
    After the nanovaccine is stored at room temperature for at least 14 days, its function remains unchanged
    .
    This study proves that stable and durable immunohydrogel-LNPs systems can be used for effective tumor immunotherapy
    .

    Schematic diagram of hydrogel-LNPs system preparation and tumor immunity in vivo

    Paper Link:

    https://doi.
    org/10.
    1002/adma.
    202205950

    https://doi.
    org/10.
    1002/adfm.
    202204636

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.